Business
Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European So...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Oct. 22, 2018\n\n\n\nTORONTO and HOUSTON, TX, Oct. 22, 2018 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA and OTCQB: MDNAF) a clinical stage immuno-oncology company, presented a poster discussion entitled \"Understanding Biological Activity, Tumor Response and Pseudoprogression in a Phase-2b Study of MDNA55 in Adults with Recurrent or Progressive Glioblastoma\" at the European Society for Medical Oncology (ESMO) Congress this past Saturday (October 20, 2018) in Munich, Germany.\nDr. Martin Bexon, Head of Clinical Development at Medicenna, presented results outlining the patterns of responses seen in the MDNA55 Phase 2b clinical trial in patients treated at low doses implemented during the first half of the study. The presentation highlighted the use of advanced imaging modalities to help response evaluation and identify treatment artefacts that can mask underlying tumor response particularly when evaluating treatments with a substantial immune mediated component, such as MDNA55. Localized inflammation occurring from treatment by immunotherapies (called pseudo-progression) is common and difficult to distinguish from true disease progression using routine clinical MRI. \n\"For MDNA55, we can first see evidence of pseudo-progression in the 30 days post-treatment,\" states Dr Bexon. \"In some cases it resolves relatively rapidly thereafter but it has also been seen to get more extensive for up to 6 months and can take over 10 months to resolve. Once the inflammation resolves, we have seen evidence of underlying tumor shrinkage and sustained disease control, despite substantial increases in initial measurements.\"\n\"It is necessary to accurately detect pseudo-progression in order to identify the treatment time course of MDNA55 and fully evaluate treatment benefit\" states Dr. John H. Sampson, MD, PhD, Chai...